Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical characteristics and disease burden in prurigo nodularis
Prachi Aggarwal, Justin Choi, Nishadh Sutaria, et al.
Clinical and Experimental Dermatology (2021) Vol. 46, Iss. 7, pp. 1277-1284
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Gil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Nature Medicine (2023) Vol. 29, Iss. 5, pp. 1180-1190
Open Access | Times Cited: 115
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
Shawn G. Kwatra, Gil Yosipovitch, Franz J. Legat, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 17, pp. 1579-1589
Closed Access | Times Cited: 56
Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo
Pavel Kolkhir, Polina Pyatilova, Tameem Ashry, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1998-2009.e5
Closed Access | Times Cited: 45
Prurigo nodularis: new insights into pathogenesis and novel therapeutics
Viviane Liao, Hannah Cornman, Emily Ma, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 6, pp. 798-810
Closed Access | Times Cited: 8
Epidemiology of prurigo nodularis: an analysis of global trends from 1998–2023
Shiyan Yang, Chunxiao Wang, Sihan Wang, et al.
Clinical Epidemiology and Global Health (2025) Vol. 31, pp. 101906-101906
Closed Access | Times Cited: 1
A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis
Chirag Vasavda, Guihong Wan, Mindy D Szeto, et al.
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 12, pp. 2416-2426.e1
Closed Access | Times Cited: 18
Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans
Nishadh Sutaria, Martin P. Alphonse, Melika Marani, et al.
Journal of Investigative Dermatology (2021) Vol. 142, Iss. 5, pp. 1300-1308.e3
Open Access | Times Cited: 34
Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment
Lai‐San Wong, Yu-Ta Yen
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12390-12390
Open Access | Times Cited: 23
The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis
Varsha Parthasarathy, Karen Cravero, Lillian Xu, et al.
Journal of the American Academy of Dermatology (2023) Vol. 88, Iss. 5, pp. 1101-1109
Open Access | Times Cited: 13
Prurigo Nodularis and Acquired Perforating Dermatosis in Chronic Kidney Disease: Are They the Same Entity?
Rami H. Mahmoud, Giulia Coscarella, Ruby Kwak, et al.
Clinics in Dermatology (2025)
Closed Access
The Big Four in the Pathogenesis and Pathophysiology of Prurigo Nodularis: Interplay among Type 2 Inflammation, Epidermal Hyperplasia, Dermal Fibrosis, and Itch from Neuroimmune Dysregulation
Takashi Hashimoto, Satoshi Okuno
Clinics in Dermatology (2025)
Closed Access
Effectiveness and Safety of Nemolizumab in Patients with Prurigo Nodularis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ahsan Raza Raja, Zoha Zahid Fazal, Aisha Sethi
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Epidemiology and Severity of Prurigo Nodularis In Europe: A Literature Review With an Application to Italian Data
Cataldo Patruno, Claudio Pelucchi, Carlotta Galeone, et al.
Dermatology Practical & Conceptual (2025) Vol. 15, pp. 4716-4716
Open Access
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years
Hiroo Yokozeki, Hiroyuki Murota, Takayo Matsumura, et al.
British Journal of Dermatology (2024) Vol. 191, Iss. 2, pp. 200-208
Open Access | Times Cited: 4
Advancing Psoriasis Care through Artificial Intelligence: A Comprehensive Review
Payton Smith, Chandler Johnson, Kathryn Haran, et al.
Current Dermatology Reports (2024) Vol. 13, Iss. 3, pp. 141-147
Open Access | Times Cited: 3
Cutaneous neuropeptides: the missing link between psychological stress and chronic inflammatory skin disease?
Jesse J. Keller
Archives of Dermatological Research (2023) Vol. 315, Iss. 7, pp. 1875-1881
Closed Access | Times Cited: 8
Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan
Hiroyuki Murota, Kazuhiko Arima, Takuo Yoshida, et al.
The Journal of Dermatology (2023) Vol. 51, Iss. 2, pp. 223-233
Open Access | Times Cited: 8
Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort
Hannah Cornman, Katherine A. Whang, Emily Ma, et al.
British Journal of Dermatology (2024) Vol. 190, Iss. 4, pp. 571-572
Closed Access | Times Cited: 2
Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Gil Yosipovitch, Brian Kim, Shawn G. Kwatra, et al.
JAAD International (2024) Vol. 16, pp. 163-174
Open Access | Times Cited: 2
Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: A real‐world evidence claims data study
Sonja Ständer, Miriam Ketz, Divine Akumo, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 5, pp. 883-894
Closed Access | Times Cited: 6
Chronic pruritus: From pathophysiology to drug design
Márcia Martins, Isabel F. Almeida, Maria Teresa Cruz, et al.
Biochemical Pharmacology (2023) Vol. 212, pp. 115568-115568
Open Access | Times Cited: 5
A review of the current management and burden of prurigo nodularis in the United States
Sarah S. Chisolm
The American Journal of Managed Care (2023) Vol. 29, Iss. Suppl 5, pp. S63-S72
Open Access | Times Cited: 4
Consenso sobre el algoritmo diagnóstico del prurigo crónico nodular
F.J. Ortiz de Frutos, E. Serra‐Baldrich, M.J. Tribó Boixareu, et al.
Actas Dermo-Sifiliográficas (2024)
Open Access | Times Cited: 1
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Shawn G. Kwatra, Gil Yosipovitch, Sonja Ständer, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 10, pp. 1965-1972
Open Access | Times Cited: 1
Current clinical practice of prurigo nodularis in Japan: A cross‐sectional web‐survey among dermatologists
Hiroyuki Murota, Mai Matsumoto, Kazuhiko Arima, et al.
The Journal of Dermatology (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top